Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2017 Publisher: TEVA UK Limited, Brampton Road, Hampden Park, Eastbourne, East Sussex, BN22 9AG, United Kingdom
Tovedeso 3.5 mg Prolonged-release Tablets.
| Pharmaceutical Form |
|---|
|
Prolonged-release tablet. The 3.5 mg tablets are light blue, oval, biconvex, film-coated, with dimensions of 11.6 mm x 6.35 mm and embossed on one side with ‘3.5’. |
Each prolonged-release tablet contains desfesoterodine succinate 3.5 mg corresponding to 2.6 mg of desfesoterodine.
Excipients with known effect: Each prolonged-release tablet contains 11.175 mg of lactose monohydrate.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Desfesoterodine |
Desfesoterodine is a competitive, specific muscarinic receptor antagonist. It is the primary active metabolite of fesoterodine, and regarded as main active pharmacological principle of fesoterodine; fesoterodine is considered as prodrug of desfesoterodine. The affinity of desfesoterodine for the muscarinic receptors is 2 orders of magnitude greater than that of fesoterodine. |
| List of Excipients |
|---|
|
Microcrystalline cellulose (Type 101) |
Aluminium-aluminium blisters containing 14, 28, 56, 84, 98, 100 or 112 tablets.
Not all pack sizes may be marketed.
TEVA UK Limited, Brampton Road, Hampden Park, Eastbourne, East Sussex, BN22 9AG, United Kingdom
PL 00289/2063
28/07/2017
| Drug | Countries | |
|---|---|---|
| TOVEDESO | Germany, Spain, Croatia |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
